Antiretroviral agents.
D000212:Acyclovir / Q000009:adverse effects* / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000998:Antiviral Agents / Q000009:adverse effects* / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D002273:Carcinogens / Q000009:adverse effects* / Q000737:chemistry; D016049:Didanosine / Q000009:adverse effects* / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D004195:Disease Models, Animal; D019317:Evidence-Based Medicine; D006801:Humans; D007408:Intestinal Absorption; D009369:Neoplasms / Q000139:chemically induced* / Q000453:epidemiology; D012307:Risk Factors; D014018:Tissue Distribution; D016047:Zalcitabine / Q000009:adverse effects* / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D015215:Zidovudine / Q000009:adverse effects* / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use
D000998:Antiviral Agents; D002273:Carcinogens; D015215:Zidovudine; D016047:Zalcitabine; D016049:Didanosine; D000212:Acyclovir